Biote (BTMD) Cash & Equivalents (2020 - 2026)

Biote has reported Cash & Equivalents for 7 years, with the latest figure at $5.3 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 87.24% year-over-year to $5.3 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 87.24% YoY), and the FY2025 full-year result was $24.1 million, down 38.68% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $5.3 million, down from $24.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $89.0 million in Q4 2023, with the low at $5.3 million in Q1 2026.
• Average Cash & Equivalents over 5 years is $51.7 million, with a median of $41.7 million recorded in 2025.
• Year-over-year, Cash & Equivalents jumped 265.57% in 2022 and sank 87.24% in 2026.
• Tracing BTMD's Cash & Equivalents over 5 years: stood at $79.2 million in 2022, then gained by 12.33% to $89.0 million in 2023, then plunged by 55.8% to $39.3 million in 2024, then tumbled by 38.68% to $24.1 million in 2025, then sank by 77.95% to $5.3 million in 2026.
• The last three Cash & Equivalents figures came in at $5.3 million (Q1 2026), $24.1 million (Q4 2025), and $28.0 million (Q3 2025), per Business Quant data.

Peer Comparison